Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Release - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - Channelchek

Summary by channelchek.com
Open the article to view the coverage from channelchek.com
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

channelchek.comchannelchek.com

Release - Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - Channelchek

Open the article to view the coverage from channelchek.com

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

channelchek.com broke the news in on Tuesday, December 16, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

New Brunswick, New Jersey icon

New Brunswick, New Jersey

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal